What is the diagnosis and management for an immunocompromised adult with bilateral lower extremity target lesions and respiratory symptoms?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diagnosis: Erythema Multiforme with Possible Mycoplasma Pneumoniae Infection

The clinical presentation of bilateral lower extremity target lesions with crusted centers combined with cold and cough symptoms in an immunocompromised patient most likely represents erythema multiforme, potentially triggered by an atypical respiratory infection such as Mycoplasma pneumoniae, though opportunistic infections must be urgently excluded through aggressive diagnostic workup.

Immediate Diagnostic Approach

Skin Lesion Evaluation

  • Obtain skin biopsy immediately from representative target lesions for histopathological examination, microbial staining (Gram stain, fungal stains), and cultures (bacterial, fungal, viral) 1
  • The early identification of an etiologic agent is essential in immunocompromised hosts because microbial resistance makes empiric treatment regimens difficult and potentially dangerous 1
  • Skin lesions, no matter how small or innocuous in appearance, should be carefully evaluated with early involvement of dermatology and infectious diseases specialists 1

Respiratory Assessment

  • Obtain chest imaging immediately - start with portable chest radiograph, but proceed to CT scan if standard radiograph is negative and clinical suspicion remains high 1, 2
  • CT imaging is particularly valuable in immunocompromised patients for detecting small nodular or cavitary lesions characteristic of opportunistic pathogens that are difficult to detect on standard chest radiographs 1, 2
  • Obtain two sets of blood cultures before initiating antibiotics 2
  • Collect respiratory specimens (expectorated sputum or deep tracheal aspirate if intubated) for Gram stain, culture, and viral testing 2

Risk Stratification by Immune Status

  • Determine CD4+ lymphocyte count if HIV-infected to guide differential diagnosis 1, 2
    • CD4+ >200 cells/μL with no systemic symptoms: unlikely to have opportunistic infections; consider common community-acquired pathogens 1, 2
    • CD4+ <200 cells/μL OR CD4+ >200 with unexplained fever, weight loss, or thrush: suspect Pneumocystis jirovecii, tuberculosis, and other opportunistic infections 1, 2
  • Assess neutrophil count and duration of neutropenia if applicable 1
    • High-risk: anticipated prolonged (>7 days) and profound neutropenia (ANC <100 cells/µL) 1
    • Low-risk: anticipated brief (<7 days) periods of neutropenia with few comorbidities 1

Differential Diagnosis Considerations

Infectious Etiologies in Immunocompromised Hosts

The differential diagnosis is broader than in immunocompetent patients and includes 1:

  • Bacterial: Pseudomonas aeruginosa (can cause folliculitis progressing to ecthyma gangrenosum), Staphylococcus aureus, Streptococcus species
  • Fungal: Aspergillus species (can cause disseminated cutaneous lesions), Cryptococcus, endemic fungi
  • Viral: Herpes simplex virus, varicella-zoster virus, cytomegalovirus
  • Atypical pathogens: Mycoplasma pneumoniae (classic trigger for erythema multiforme with respiratory symptoms)

Non-Infectious Etiologies

Consider 1:

  • Drug eruption (review all medications)
  • Chemotherapy- or radiation-induced skin reactions
  • Graft-versus-host disease (if transplant recipient)
  • Sweet syndrome
  • Leukocytoclastic vasculitis

Empirical Treatment Strategy

Broad-Spectrum Antimicrobial Coverage

Initiate immediate empirical therapy with vancomycin PLUS an antipseudomonal beta-lactam 3:

  • Vancomycin: 30-60 mg/kg/day in divided doses, targeting trough 15-20 μg/mL for MRSA and resistant gram-positive coverage 3
  • Antipseudomonal beta-lactam: cefepime, meropenem, or piperacillin-tazobactam for broad gram-negative coverage including Pseudomonas 3

Rationale for Broad Coverage

  • Immunocompromised patients are at risk for infections from diverse organisms, including bacteria not typically pathogenic in healthy hosts 3
  • Many infections are hospital-acquired with mounting resistance among both gram-positive and gram-negative bacteria, making narrow empirical regimens dangerous 3
  • Delaying broad-spectrum antibiotics while awaiting culture results can lead to rapid deterioration 3

Critical Pitfall to Avoid

Do NOT use Bactrim (trimethoprim-sulfamethoxazole) monotherapy empirically - this leaves dangerous gaps in coverage for Pseudomonas, Streptococcus, and anaerobes 3

Specific Considerations for Target Lesions

If Pseudomonas Folliculitis Suspected

  • Monitor daily for progression from folliculitis to ecthyma gangrenosum, which requires aggressive IV therapy 4
  • Consider ciprofloxacin 400 mg IV every 8 hours for severe disease in immunocompromised patients 4
  • Obtain cultures to confirm Pseudomonas aeruginosa and guide susceptibility-directed therapy 4

If Aspergillus Infection Suspected

  • Systemic antifungal therapy is the mainstay of treatment 1
  • Surgical debridement may be necessary for localized lesions, though it may increase mortality in neutropenic patients 1
  • Control predisposing factors by decreasing corticosteroid dosage or awaiting resolution of neutropenia 1

Respiratory Infection Management

Pneumonia Diagnosis Criteria

Diagnose pneumonia when a new pulmonary infiltrate appears on chest imaging combined with any two of three clinical features 2:

  • Fever (temperature >37.8°C)
  • Leukocytosis or leukopenia
  • Purulent respiratory secretions

Bronchoscopy Indications

Perform bronchoscopy with bronchoalveolar lavage when 2:

  • Patient cannot produce adequate sputum
  • Suspected opportunistic infections
  • Pneumonia fails to respond to empiric therapy
  • Quantitative cultures needed to distinguish colonization from true infection

Viral Pathogen Testing

Routine testing for noninfluenza respiratory viruses is strongly supported in immunocompromised populations given the high risk of progression from upper respiratory viral infection to fatal pneumonia 2

De-escalation Strategy

After 48-72 hours, reassess based on 3:

  • Clinical response to therapy
  • Culture and susceptibility results
  • Biopsy findings if obtained
  • Adjust antibiotics to narrower spectrum based on identified pathogens

If clinical improvement does not occur within 72 hours, reassess diagnosis and consider alternative or combination therapy 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diagnosing Pneumonia in Immunocompromised Hosts

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Management of Skin Infections in Immunocompromised Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Pseudomonas Folliculitis Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.